아시아 태평양 고급 상처 치료 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

아시아 태평양 고급 상처 치료 시장 분석

상처 감염은 환자의 삶의 질에 영향을 미치므로 효과적인 치유 방법이 필요합니다. 드레싱, 이종이식, 합성 이식, 치료 장치를 포함한 생물학적 제품을 포함하여 여러 종류의 상처 치유 방법이 있습니다. 당뇨병과 관련된 만성 상처의 증가와 수술 절차를 받는 환자 수의 증가는 시장에 수익성 있는 성장을 제공합니다. 시장 성장을 촉진하는 또 다른 요인은 상처 치료의 기술적 발전입니다.

아시아 태평양 고급 상처 치료 시장 규모

아시아 태평양 지역의 첨단 상처 치료 시장 규모는 2023년에 25억 3천만 달러로 평가되었으며, 2031년까지 44억 1천만 달러에 도달할 것으로 예상됩니다. 2024년에서 2031년까지의 예측 기간 동안 연평균 성장률은 7.2%입니다.

보고 범위 및 시장 세분화       

아시아 태평양 고급 상처 치료 시장 정의

Wounds are defined as the breakdown of any protective function of the skin with or without the loss of the underlying connective tissue. Wounds are formed due to several reasons, including cuts, chemical exposure, friction, shear force, and diseases, among others. There are several kinds of wounds depending upon the severity and nature, including class I, class II, class III, and class IV. Wounds can be treated as primary or secondary intention depending upon the close or open wounds, among others.

Advanced Wound Care Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail as below:

Drivers

• Increasing Cases of Chronic Wounds

Rapidly growing incidence of diabetes and chronic wounds is a major factor contributing to the growth of this market. Chronic diseases are among the most predominant and expensive health situations worldwide. Chronic diseases include diabetes, cancer, stroke, heart disease, hypertension, arthritis, respiratory diseases, oral diseases, and obesity. These can lead to long-term disability and hospitalization, which may reduce the quality of life and, ultimately, death.

In some parts of New Zealand, the rising incidence of early occurrence of type 2 diabetes is seen in many people. This has a certain risk of early death coupled with complications, including problems related to cardiac health. Some of the reasons responsible for the occurrence of chronic wounds such as the growing aging population and the increasing prevalence of diseases like overweight, hypertension, and the late side effects of radiation therapy.

For instance,

• According to IDF Diabetes Atlas, it is estimated that more than 96,000 children and adolescents under the age of 15 are diagnosed with type 1 diabetes every year, and 132,600 when the age number exceeds 20 years.

Chronic diseases are rapidly increasing day by day in many countries, and the Asia-Pacific accounts for the most number of cases of chronic diseases. The average suffering rate due to chronic disease is 7 out of 10 people, and increasing prevalence of chronic wounds such as diabetic ulcers and foot ulcers. Hence they need to go for various surgeries. Thus, the rising incidence of diabetes and associated chronic wounds will have an impact on the advanced wound care market, which will propel the market in the futuristic period.

• New Product Launches

Conventional wound care products are replaced with advanced wound care products due to their increased efficacy and effectiveness in managing wounds by offering rapid healing. The companies, including B. Braun Melsungen AG, Coloplast Group, and Integra LifeSciences, among others, are taking initiatives to launch new products with advanced technologies.

For instance,

• In May 2020, Integra LifeSciences announced a positive clinical result for Integra Bilayer Wound Matrix (IBWM). This product is part of the company’s regenerative technology portfolio, which uses collagen and amniotic products.

To attract more customers and to create new marketing opportunities for growing companies engaged in advanced wound care, healthcare professionals and researchers are developing new and innovative products, and this leads to the growth of the advanced wound care market.

• Increasing Number of Patients Undergoing Surgical Procedures

According to National Center for Biotechnology Information, wound infection is an important issue observed in surgical sections. The cause of infection is associated with the patient and their disease. Also, the wound infection depends on age, gender, contamination of the wound, time and type of operation and anesthesia, hospitalization duration, and wound drainage.

As per National Center for Biotechnology Information, approximately 6.5 million patients are affected by chronic wounds. It is estimated that more than USD 25 billion is spent per year on the treatment of chronic wounds. This is tremendously increasing due to the rising aging population, healthcare expenses, and diabetic and obese population in the Asia-Pacific region.

About 72% of patients with pressure ulcers at the age of 65 years underwent surgery. Among those hospitalized patients, about 9 out of 10 were covered by government health programs, in which around 66% and 23% were covered by Medicare state and Medicaid programs, respectively. Patients diagnosed with pressure ulcers are generally admitted to the hospital for medical reasons rather than pressure ulcers. The pressure ulcer patients are diagnosed with pneumonia, urinary tract infections (UTI), septicemia, respiratory failure, congestive heart failure (CHF), and critical diabetes mellitus (DM). The number of hospital patients who develop pressure ulcers has increased by approximately 63% in the last decade.

Opportunities

• Growth Potential in Emerging Economies

For the wound care practitioner, the most advanced dressings in developing countries are important. These materials are made of a wide range of products such as polyurethane, alginic acid salts, and other polysaccharides that are gelable; these products are used in wound care in developed countries. The circumstances are different in developing economies where traditional agents such as chlorhexidine, sodium hypochlorite, cetrimide, hydrogen-peroxide, and others are commonly available to wound care providers. Wound healing is an important process, and as the wound moves towards healing, the quality specification of a dressing increases.

For instance,

• According to World Health Organization, approximately 400 million people worldwide are dealing with diabetes. In developing countries, the age of diabetes is 45–64. By 2030, developing countries are predicted to have more people with diabetes, about 82 million of which are 65 years of age, than developed countries (48 million). The diabetic population has at a major risk of foot ulcers. Thus, this will directly affect on advanced wound care.

China's increasing technological advancement involves the treatment of wound care for better products and dressings to widen the market. The aging population of China is becoming increasingly prone to chronic, unhealing wounds due to complications such as cardiovascular diseases, obesity, and diabetes. In rural areas with poor access to health care, traditional treatments such as sutures, specialized wound dressings, and tools for wound debriding tend to gain acceptance. Many patients from all over the world are heading to countries in Asia-Pacific to get medical treatment as they need to save the expenditures on treatments. India and Thailand are the top destinations for medical tourism. Cost is often a highly concerning reason that patients are traveling for medical treatment.

• According to an article published in IJITEE, India is one of the major countries in medical tourism compared to other countries. Patients are enthusiastically approaching India because of prices, weather, community, and holidays. , The arrival of foreign tourists in India for medical treatment in the year 2015 is more than 7101.9. The annual growth rate is around 30%, and the profits earned at the end of 2015 were around USD 1482 million. Because of economic health services, 150,000 customers travel to India each year.

In various developing economies, treatable wounds and medical tourism are the major reasons for the development of advanced wound care. Most of the advanced dressings need to be available in the market in developing countries for wound care. New technologies and products for wound care are introduced in developing countries. Thus, this will help to maximize the growth of the advanced wound care market in developing countries.

Restraints/Challenges

However, the barriers to advanced wound care techniques and the high cost of the treatment process in some regions may impede the growth of advanced wound care, which is hampering the growth of the market. Additionally, high competition in medical technology industries and long lead time for the overseas qualification can be challenging factors for the growth of the market

This advanced wound care market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lung cancer surgery market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you to make an informed market decision to achieve market growth.

Asia-Pacific Advanced Wound Care Market Scope

Asia-Pacific advanced wound care market is segmented into product type, wound type, wound class, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

• Dressing
• Biologics
• Therapy Devices
• Others

Wound Class

• Class I
• Class II
• Class III
• Class IV

Wound Care

• Primary Wound Care
• Secondary Wound Care

End User

• Hospitals
• Wound Care Centers
• Ambulatory Centers
• Home Healthcare
• Clinics
• Others

Distribution Channel

• Direct Tender
• Retail

Advanced Wound Care Market Regional Analysis

The advanced wound care market is analysed, and market size insights and trends are provided by country, product type, wound type, wound class, end user, and distribution channels, as referenced above.

Countries covered in Asia-Pacific advanced wound care market are Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines and Rest of the Asia-Pacific.

Japan dominates the Asia-Pacific advanced wound care market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the rising need for the verification and validation of wound care treatment processes in the region, and rapid research development is boosting the market

The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Advanced Wound Care Market Share

고급 상처 치료 시장 경쟁 구도는 경쟁자들의 세부 정보를 제공합니다. 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 포함됩니다. 위에 제공된 데이터 포인트는 회사가 고급 상처 치료 시장에 집중하는 것과만 관련이 있습니다.

시장에서 운영되는 고급 상처 관리 시장 리더는 다음과 같습니다.

• 스미스 앤 네퓨
• 3M
• 메드라인 인더스트리 주식회사
• 묄린리케 헬스케어 AB
• 콘바텍 주식회사
• 백스터
• 카디널 건강
• L&R 그룹
• HARTMANN USA, Inc. (PAUL HARTMANN AG의 자회사)
• 미메드엑스
• 존슨앤존슨 서비스 주식회사
• 인테그라 라이프사이언스 코퍼레이션
• 콜로플라스트 그룹
• B. 브라운 멜선겐 AG
• 메드트로닉, 홀리스터 주식회사
• 짐머 바이오멧
• 엘켐실리콘(중국국립블루스타(그룹)유한회사의 자회사)

고급 상처 치료의 최신 개발

• 2020년 8월, Medline Industries, Inc.는 북동부 지역에서 서비스를 확장하여 사업을 확장했습니다. 이 회사는 매사추세츠주 억스브리지에 새로운 제품 유통 시설을 열었습니다. 이 이니셔티브는 회사의 제품 유통 네트워크를 강화하고 고급 상처 치료 시장에서 더 많은 수익을 창출할 수 있게 해주었습니다.
• 2020년 2월, Baxter는 Sanofi로부터 Seprafilm Adhesion Barrier를 인수했습니다. 인수한 제품은 복부 및 특정 골반 수술 시 접착의 심각성을 줄이기 위한 보조제로 사용됩니다. 이 인수를 통해 회사는 첨단 상처 치료 시장에서 뿌리를 내릴 수 있었습니다.

SKU-1514